Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants
HALEON AUSTRALIA PTY LTD
For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries
1 trial -
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors
Genmab A/S
Advanced solid tumors
1 trial -
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.
Novartis Pharmaceuticals
Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma
1 trial -
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL
Novartis Pharmaceuticals
Relapsed/refractory Non Hodgkin Lymphoma
1 trial -
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie Deutschland GmbH & Co. KG
Non-Hodgkin's Lymphoma
1 trial -
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie Deutschland GmbH & Co. KG
Select B-Cell malignancies.
1 trial -
Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.
The George Institute
Idiopathic Pulmonary Fibrosis
1 trial -
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
Celgene Europe Limited
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
1 trial -
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy
Samsung Bioepis NL B.V.
Non-small cell lung cancer
1 trial -
Subconjunctival aflibercept
Regeneron UK Limited
Corneal Neovascularization
1 trial -
Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Amgen
Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
1 trial -
T cell injection targeting CD7 chimeric antigen receptor
The First People's Hospital of Lianyungang
CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
1 trial -
T cell injection targeting CD7 chimeric antigen receptor
The First People's Hospital of Lianyungang
T Lymphoblastic Leukemia/Lymphoma
1 trial -
TAEST16001
Chongqing Precision Biotech Co., Ltd
Liver Cancer Stage IV
1 trial -
TAK-164
Takeda
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
1 trial -
TAK-935
Takeda
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
1 trial -
TD-1607
Theravance Biopharma Ireland Umited
Serious Infections Due to Known or Suspected Gram-positive Pathogens
1 trial -
TN-401
Tenaya Therapeutics
Arrhythmogenic Right Ventricular Cardiomyopathy
1 trial -
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
Disc Medicine
Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma
1 trial -
Target CD7 CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-cell Acute Lymphoblastic Leukemia
1 trial -
Targeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Advanced Lung Cancer
4 trials -
Tarlatamab
BEONE MEDICINES AUS PTY LTD
Extensive Stage Small Cell Lung Cancer
1 trial -
Tarlatamab
Amgen
Neuroendocrine Prostate Cancer
1 trial -
Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
S.L
Healthy Adult Subjects
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources